TELA Bio Inc at JMP Securities Life Sciences Conference Transcript

Jun 16, 2022 / 01:30PM GMT
David Turkaly - JMP Securities LLC - Analyst

This is the one we've been waiting for.

Tony Koblish - TELA Bio, Inc. - Co-Founder, President & CEO

All right, David. Appreciate it.

Questions and Answers:

David Turkaly - JMP Securities LLC - Analyst

Yes, this is TELA Bio, one of our top picks. We have Tony and Roberto from the Company here with me. Obviously the last couple years have been challenging for a number of reasons, but I feel like you guys have managed to grow really well through it. So, I guess talk a little bit about what's gone on hernia with COVID and now beyond -- hopefully, beyond sort of what you're seeing from a volume or rebound in hernia procedures?

Tony Koblish - TELA Bio, Inc. - Co-Founder, President & CEO

Yes. So, we likely were the last MedTech company, one of the last MedTech companies to go public before COVID hit. And then we were implementing our first big GPO contract with HealthTrust in March of 2020 just as COVID hit. And what we
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot